Seres Therapeutics Inc reports results for the quarter - Earnings Summary

• Seres Therapeutics Inc MCRB.OQ reported quarterly adjusted earnings of 58 cents​​ per share for the quarter , higher than the same quarter last year, when the company reported EPS of -37 cents. The mean expectation of six analysts for the quarter was for a loss of 25 cents per share. Wall Street expected results to range from -26 cents to -23 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Seres Therapeutics Inc's reported EPS for the quarter was 58 cents​.

• The company reported quarterly net income of $88.78 million.

• Seres Therapeutics Inc shares had fallen by 29.8% this quarter and lost 52.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.7% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and 2 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Seres Therapeutics Inc is 1.25

This summary was machine generated from LSEG data November 13 at 03:25 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)